Back to Oncology
OncologyvModifiedEvidence-Based

Modified Glasgow Prognostic Score (mGPS) for Cancer Outcomes

Provides improved cancer prognosis over the original Glasgow Prognostic Score, based on serum biomarkers (CRP and albumin) reflecting systemic inflammation and nutritional status

Clinical Input Parameters

mg/L
Range: 0 — 500 mg/L
g/L
Range: 10 — 60 g/L
Clinical Assessment
Awaiting Parameters
mgps score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Modified Glasgow Prognostic Score (mGPS) for Cancer Outcomes is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within oncology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Score determined by CRP and albumin levels. Score 0: CRP ≤10 mg/L (any albumin). Score 1: CRP >10 mg/L and albumin ≥35 g/L. Score 2: CRP >10 mg/L and albumin <35 g/L.

Clinical Pearls & Practice Notes

  • Modified version weighs inflammatory component (CRP) more heavily than original GPS
  • Low albumin alone (without elevated CRP) scores 0 points in mGPS vs 1 point in original GPS
  • Validated across multiple cancer types including gastric, renal, lung, pancreatic, and colorectal cancers
  • Reflects both systemic inflammatory response and nutritional status
  • Higher scores associated with worse overall survival, disease-specific survival, and disease-free survival
  • Uses readily available laboratory markers
  • Should be interpreted in context of cancer stage, treatment status, and other prognostic factors
  • Not a standalone diagnostic or treatment decision tool
  • Survival outcomes vary significantly based on patient selection and cancer type
  • Can provide prognostic information beyond traditional TNM staging

Evidence & Literature Citations

  1. Proctor MJ, Morrison DS, Talwar D, Balmer SM, O'Reilly DS, Foulis AK, Horgan PG, McMillan DC. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer. 2011 Aug 23;105(5):726-34. doi: 10.1038/bjc.2011.292.
  2. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013 Aug;39(5):534-40. doi: 10.1016/j.ctrv.2012.08.003.
  3. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003 Aug 4;89(3):477-81. doi: 10.1038/sj.bjc.6601242.

Score Interpretation Ranges

Score 00 – 0 pts

Good prognosis

Score 11 – 1 pts

Intermediate prognosis

Score 22 – 2 pts

Poor prognosis

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.